Synopsis: The shares of this pharmaceuticals stock was in the spotlight today as the company declared its Q2 results with a robust 195 percent growth in its profit along with 65 percent growth in its Revenue.
The shares of this company, which is engaged in the manufacturing and selling of bulk drugs and caters to both domestic and international markets, were in action today as the company in its Q2 Results showed growth in several performance metrics.
With a market cap of Rs 23,320 crore, the shares of Neuland Laboratories Ltd soared 11 percent hitting an intraday high of Rs 19748.40 when compared to its previous day closing price of Rs 17821.50 , today’s intraday high also marks its 52 week high. The shares have given a return of 1,435 percent over the last 5 years.
Q2 FY26 Result highlights.
The Revenue from operations for the company stood at Rs 514.27 crore when compared to Rs 310.84 crore in Q2 FY25, growing by about 65 percent YoY and on QoQ increasing by 76 percent from Rs 292.75 crore in Q1 FY26.
The Profit after tax grew by about 195 percent YoY when you compare the Q2 FY26 at Rs 96.85 crore to Rs 32.84 crore in Q2 FY25, and on QoQ basis has increased 597 percent from Rs 13.90 crore in Q1 FY26.
Working capital days of sale at 155 days in Q2FY26 as against 145 days in Q1FY26, mainly on account of increase in receivables. Capex outflow of Rs 170 Crore in H1FY26. In this quarter the company had its revenue segmented as follows:
60 percent from CMS, 26 percent from Prime, 11 percent from Speciality and the remaining 3 percent from others.
The promoters of Neuland Laboratories Sucheth Davuluri and Saharsh Davuluri, say that;
“The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.”
“Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.”
About the company and others.
Neuland Laboratories is a global provider of API Contract Development and Manufacturing Organization (CDMO) services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex active pharmaceutical ingredients (APIs) and develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing.
As of September 2025, Ace investor Mukul Mahavir Agrawal holds 3.12 % stake in the company , fresh stake was added by him in the month of September 2020. Another Ace investor Vedia kedia through kedia securities private ltd holds 1.01% stake in the company.
Neuland Laboratories has a strong presence in more than 80 countries, with Europe (48 percent) and North America (44 percent) as key markets , Other regions like APAC (3 percent), MENA (2 percent), and Latin America (1 percent) also contribute to its global reach. Its headquarters and three manufacturing units are based in Hyderabad, India, serving as the backbone of its worldwide operations.
Written by Leon Mendonca.
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
